Chemomab Therapeutics (NASDAQ:CMMB) Announces Earnings Results

Chemomab Therapeutics (NASDAQ:CMMB – Get Free Report) issued its earnings results on Thursday. The company reported ($0.26) EPS for the quarter, beating analysts’ consensus estimates of ($0.40) by $0.14, Zacks reports. During the same period in the previous year, the company posted ($0.72) earnings per share. Chemomab Therapeutics Stock Down 3.1 % Shares of NASDAQ:CMMB […]

Related Keywords

Roth Mkm ,Renaissance Technologies ,Nasdaq ,Citadel Advisors ,Boothbay Fund Management ,Chemomab Therapeutics Company Profile ,Envestnet Asset Management Inc ,Chemomab Therapeutics Ltd ,Chemomab Therapeutics ,Get Free Report ,Therapeutics Stock Down ,Asset Management ,Fund Management ,Two Sigma Investments ,Therapeutics Ltd ,Chemomab Therapeutics Daily ,